Thursday, September 07, 2017 8:41:52 AM
It's not going to come to that. Jenny isn't going to jail over 40,000 personal shares.
That said, I have worked with several SEC attorneys in the past and would be more than willing to reach out if there were conclusive evidence of vote tampering, etc, to the detriment of the shareholders.
My belief has always been that because Jenny owns so few shares, she would be willing to file BK out of spite. I still believe that will happen.
However, I also believe that in a BK scenario the judge would look at the value of the Delcath technology as it would be sold for in an open bid, and would look at the amount of debt outstanding, and would rule that rather than restructure by wiping out old shares and giving new equity to the creditors, the easier and more equitable way to repay the debt would simply be to liquidate the company's assets.
The UCC would have a very, very difficult time proving that Chemosat is worth less than what they are owed. And a judge would say, fine, let's find out by conducting a market test with a reserve bid value of $15M.
That said, I have worked with several SEC attorneys in the past and would be more than willing to reach out if there were conclusive evidence of vote tampering, etc, to the detriment of the shareholders.
My belief has always been that because Jenny owns so few shares, she would be willing to file BK out of spite. I still believe that will happen.
However, I also believe that in a BK scenario the judge would look at the value of the Delcath technology as it would be sold for in an open bid, and would look at the amount of debt outstanding, and would rule that rather than restructure by wiping out old shares and giving new equity to the creditors, the easier and more equitable way to repay the debt would simply be to liquidate the company's assets.
The UCC would have a very, very difficult time proving that Chemosat is worth less than what they are owed. And a judge would say, fine, let's find out by conducting a market test with a reserve bid value of $15M.
Recent DCTH News
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
